The Phase Two Trial of the HIV Vaccine

HIV is notoriously slippery as a target. It continues to evolve and change its appearance. We're going after just one part of the envelope that we know is a target for neutralization but there are others, seven or eight of them. The vaccine that we come up with will likely have to target more than one site. And so we're now looking at the second step, the booster.